Myosteatosis in a systemic inflammation-dependent manner predicts favorable survival outcomes in locally advanced esophageal cancer by Gabiatti, Camila T. B. et al.
UNIVERSIDADE ESTADUAL DE CAMPINAS
SISTEMA DE BIBLIOTECAS DA UNICAMP
REPOSITÓRIO DA PRODUÇÃO CIENTIFICA E INTELECTUAL DA UNICAMP
Versão do arquivo anexado / Version of attached file:
Versão do Editor / Published Version
Mais informações no site da editora / Further information on publisher's website:
https://onlinelibrary.wiley.com/doi/full/10.1002/cam4.2593
DOI: 10.1002/cam4.2593
Direitos autorais / Publisher's copyright statement:
©2019 by John Wiley & Sons. All rights reserved.
DIRETORIA DE TRATAMENTO DA INFORMAÇÃO
Cidade Universitária Zeferino Vaz Barão Geraldo
CEP 13083-970 – Campinas SP
Fone: (19) 3521-6493
http://www.repositorio.unicamp.br
Cancer Medicine. 2019;8:6967–6976.    | 6967wileyonlinelibrary.com/journal/cam4
Received: 4 July 2019 | Revised: 8 September 2019 | Accepted: 15 September 2019
DOI: 10.1002/cam4.2593  
O R I G I N A L  R E S E A R C H
Myosteatosis in a systemic inflammation‐dependent manner 
predicts favorable survival outcomes in locally advanced 
esophageal cancer
Camila T. B. Gabiatti |   Mariane C. L. Martins |   Daniela L. Miyazaki |   Leandro P. Silva |   
Fabiana Lascala |   Ligia T. Macedo |   Maria Carolina Santos Mendes |    
José Barreto Campello Carvalheira
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd
Division of Oncology, Department of 
Internal Medicine, Faculty of Medical 
Sciences, State University of Campinas 
(UNICAMP), Campinas, SP, Brazil
Correspondence
José Barreto Campello Carvalheira, 
Department of Internal Medicine, FCM‐
State University of Campinas (UNICAMP), 
MA: 13083‐970, Campinas, SP, Brazil.
Email: jbcc@g.unicamp.br
Funding information
Fundação de Amparo à Pesquisa do Estado 
de São Paulo, Grant/Award Number: 
2018/23428‐0; Conselho Nacional de 
Desenvolvimento Científico e Tecnológico, 
Grant/Award Number: 302535/2018-7
Abstract
Increased adiposity and its attendant metabolic features as well as systemic inflam-
mation have been associated with prognosis in locally advanced esophageal cancer 
(LAEC). However, whether myosteatosis and its combination with systemic inflam-
matory markers are associated with prognosis of esophageal cancer is unknown. Our 
study aimed to investigate the influence of myosteatosis and its association with 
systemic inflammation on progression‐free survival (PFS) and overall survival (OS) 
in LAEC patients treated with definitive chemoradiotherapy (dCRT). We retrospec-
tively gathered information on 123 patients with LAEC submitted to dCRT at the 
University of Campinas Hospital. Computed tomography (CT) images at the level of 
L3 were analyzed to assess muscularity and adiposity. Systemic inflammation was 
mainly measured by calculating the neutrophil‐to‐lymphocyte ratio (NLR). Median 
PFS for patients with myosteatosis (n = 72) was 11.0 months vs 4.0 months for pa-
tients without myosteatosis (n = 51) (hazard ratio [HR]: 0.53; 95% confidence inter-
val [CI], 0.34‐0.83; P = .005). Myosteatosis was also independently associated with 
a favorable OS. Systemic inflammation (NLR > 2.8) was associated with a worse 
prognosis. The combination of myosteatosis with systemic inflammation revealed 
that the subgroup of patients with myosteatosis and without inflammation presented 
less than half the risk of disease progression (HR: 0.47; 95% CI: 0.26‐0.85; P = .013) 
and death (HR: 0.39; 95% CI, 0.21‐0.72; P  =  .003) compared with patients with 
inflammation. This study demonstrated that myosteatosis without systemic inflam-
mation was independently associated with favorable PFS and OS in LAEC patients 
treated with dCRT.
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1 |  INTRODUCTION
Despite the recent advances in esophageal cancer treat-
ment, this malignancy is still associated with a poor prog-
nosis even before it evolves to advanced stage.1 Clinically, 
this neoplasm is characterized by digestive tract obstruc-
tion, which results in malnutrition and its accompanying 
body composition changes.2 Given that weight loss is re-
ported in approximately 79% of esophageal cancer patients 
and maintenance of nutrition is one of the biggest treatment 
challenges,2 it is not surprising that markers of nutritional 
status are associated with prognosis. For instance, preoper-
ative severe weight loss has been associated with decreased 
overall survival (OS) after esophageal cancer resection.3 
Interestingly and in opposition to other malignancies, di-
abetes was associated with better prognosis.4 Moreover, a 
large prospective study showed a strong relationship be-
tween high body mass index (BMI) and fewer deaths from 
squamous cell carcinoma of the esophagus.5 Thus, the 
identification of nutritional‐related features that predict 
esophageal cancer clinical outcomes has the potential to 
improve treatment strategies by allowing a patient‐person-
alized therapeutic plan.
Cachexia syndrome, and its attendant complications, is 
one of the most prevalent causes of death in cancer patients.6 
Computed tomography (CT) evaluation of adiposity and 
muscularity measured at the level of the third lumbar vertebra 
is highly correlated with body composition7 and has become 
a standard tool for caquexia assessment.8 Sarcopenia and de-
creased muscle radiodensity are the most prominent studied 
parameters in CT evaluations. Sarcopenia is a key feature 
of cachexia syndrome,9 as such it is a predictor of poorer 
OS as well as increased cancer recurrence in distinct can-
cers.10-12 Accordingly, sarcopenia is correlated with higher 
rates of treatment‐related complications13,14 and poor prog-
nosis in surgically treated esophageal cancer.15 In contrast, it 
was not yet associated with survival outcomes in metastatic 
settings.16 Decreased muscle radiodensity, mainly caused by 
intramyocellular triglycerides (myosteatosis), is also associ-
ated with poor survival outcomes in distinct tumours.12,17-19 
Importantly, myosteatosis is not directly biologically cor-
related with sarcopenia, nor is part of cachexia definition.20 
Nonetheless, whether myosteatosis predicts esophageal can-
cer survival outcomes has not been assessed yet.
Cancer cachexia is mediated by complex host‐tumor 
cross‐talks that results in a series of tumor‐secreted proin-
flammatory factors, leading to anorexia as well as muscle 
weaning and lower adipose tissue depots.6 Consistently, a re-
cent report evaluating the combined analysis of body compo-
sition and systemic inflammatory indexes demonstrated that 
colorectal cancer patients with sarcopenia and inflammation 
(neutrophil‐to‐lymphocyte ratio [NLR] higher than 3) had 
twofold increase in the risk of death.10
In contrast to the canonical pathophysiology of cancer 
cachexia, locally advanced esophageal cancer (LAEC)‐me-
diated mechanical obstruction of digestive tract triggers a 
unique kind of cancer cachexia, since the mechanical ob-
struction is the preponderant pathophysiological factor for its 
development.2 Congruent with a low ingestion, malnutrition 
was more frequently reported in individuals with esophageal 
cancer in a study that evaluated 1000 patients with differ-
ent cancer types.21 However, a systematic characterization of 
body composition and its combination with systemic inflam-
matory indexes influence on survival outcomes of LAEC 
treated with definitive chemoradiotherapy (dCRT) is yet to 
be determined. Therefore, in the present analysis, we retro-
spectively evaluated myosteatosis and sarcopenia as well as 
systemic inflammatory indexes as possible prognostic factors 
in patients with esophageal carcinoma.
2 |  MATERIAL AND METHODS
2.1 | Patients and procedures
In this retrospective study, between January 2010 and 
December 2016, we identified a total of 181 patients di-
agnosed with LAEC treated at Campinas State University 
Hospital. Inclusion criteria were as follows: (a) histologi-
cally confirmed esophageal squamous cell carcinoma or 
adenocarcinoma; (b) patients submitted to dCRT; (c) ab-
dominal CT scans performed within 4 months of diagnosis 
that were assessed electronically in the Picture Archiving and 
Communication System; and (d) availability of clinical, de-
mographic, and anthropometric data of interest. Patients who 
underwent esophagectomy, received chemotherapy or radio-
therapy exclusively, with a second cancer not in esophagus, 
or with death event occurring up to 30 days following diag-
nosis, were excluded from this study.
Medical records were considered for data collection from 
the diagnosis date until the last date of follow‐up or death. 
Clinical evaluation and assessment of abdominal and thoracic 
CTs were performed routinely for follow‐up for progression‐
free survival (PFS). Eastern Cooperative Oncology Group 
(ECOG) performance status and BMI were determined by 
functional status and anthropometric measurements (height 
and weight), respectively, checked by hospital staff.
This study was approved by the Campinas State University 
Institutional Review Board (2.239.135), with a waiver of in-
formed consent.
2.2 | Body composition
The CT scans used for analysis were carried out as part of 
diagnostic and staging purposes. Muscle area, muscle ra-
diodensity, and adiposity were measured from CT scans 
within 4 months of diagnosis and before chemotherapy and 
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radiation (median [range], 1.1 [−3.2 to 3.8] months after di-
agnosis), by a single trained researcher who was blinded to 
outcome assessment, using Slice‐OMatic Software, version 
5.0 (Tomovision™).8,22,23
The average of two consecutive axial images at the level 
of L3 was considered for body composition quantification, 
including total skeletal muscle (SM), visceral (VAT) and in-
tramuscular adipose tissue (IMAT) cross‐sectional areas, and 
mean muscle attenuation (MA). Tissue areas were identified 
by their anatomic features and quantified according to the 
standard Hounsfield unit (HU) range of −29 to 150 for SM, 
−150 to −50 for VAT, and −190 to −30 for IMAT and sub-
cutaneous adipose tissue.24,25
Skeletal muscle index (SMI), visceral fat index (VFI), and 
subcutaneous fat index (SFI) were calculated from total adipose 
and muscle mass cross‐sectional area divided by height square 
(cm2/m2). The MA in HU was also reported for the whole muscle 
area at L3. As previously described by Martin et al, the follow-
ing parameters were used to define sarcopenia (SMI < 41 cm2/
m2 for women; SMI  <  43  cm2/m2 if BMI  <  25  kg/m2; and 
SMI < 53 cm2/m2 if BMI ≥ 25 kg/m2 for men) and myoste-
atosis (MA < 41 HU if BMI < 25 kg/m2 and MA < 33 HU 
if BMI  ≥  25  kg/m2).22 Visceral obesity was established as 
VAT > 80.1 cm2 for females and VAT > 163.8 cm2 for males.26
2.3 | Systemic inflammatory indexes
Complete blood count routinely collected for initiation of chem-
otherapy was used to calculate NLR by dividing neutrophils by 
lymphocyte absolute counts. We categorized this index using the 
median value, which fell in a meaningful clinical value of 2.8.27 
Likewise, platelet‐to‐lymphocyte ratio (PLR) was obtained 
using platelets in the numerator of the previous ratio instead 
of neutrophils. For analysis, this variable was also categorized 
using the median value (133), which fell in a range that is often 
used in other studies to categorize this inflammatory index.28
2.4 | Treatment toxicity
All data on treatment toxicity (eg, hematologic disorders, 
nausea, vomit, diarrhea, etc) were reviewed from medical re-
cords. Treatment toxicity was dichotomized into present or 
absent and any type of grade 3 or 4 toxicity according to the 
Common Terminology Criteria for Adverse Events [CTCAE 
v4.03]).29 Carboplatin plus paclitaxel or 5‐fluorouracil asso-
ciated with cisplatin was selected at the discretion of the at-
tendant physician as the first‐line chemotherapy regimen and 
radiotherapy at a median dosage of 50 Gy.
2.5 | Endpoints
The co‐primary endpoints were OS (calculated by time be-
tween LAEC diagnosis and death from any cause) and PFS 
(two distinct calculations: time between the diagnosis and 
disease progression or death; or the date of performed CT and 
disease progression or death) and response rate. In the event 
of patients who were still alive, censoring occurred at the last 
follow‐up date registered in the medical record.
2.6 | Statistical analysis
The relationships between myosteatosis and continuous 
variables were assessed by Student's t test (presented as 
mean ± SD) or Wilcoxon rank‐sum test (presented as me-
dian  ±  interquartile range30) for parametric and nonpara-
metric distributions, respectively. Categorical variables 
were presented as proportions and analyzed by Chi‐square 
or Fisher exact tests, depending on the distribution of the 
variable. Kaplan‐Meier curves, log‐rank tests, univariate and 
multivariate Cox proportional hazards were applied to ana-
lyze the impact of myosteatosis and sarcopenia on survival 
outcomes. To identify variables that interfered in outcomes, 
all values P < .1 in the univariate analyses were included in 
the multivariate Cox regression model. Sensitivity analysis 
was performed to reduce the probability of reverse causal-
ity excluding patients who died within 3  months after the 
diagnosis of LAEC. Effect modification analyses were then 
performed, aiming for subgroup differences. Overall survival 
and PFS were evaluated using the nonparametric Kaplan‐
Meier method. All statistical analyses were performed using 
Stata software, version 12.0 (StataCorp LP®). Statistical sig-
nificance was established with two‐sided P value < .05.
3 |  RESULTS
3.1 | Patient and body composition 
characteristics
Among the 181 patients treated for LAEC between January 
2010 and December 2016, 123 patients met the inclusion 
criteria. Median follow‐up time was 10.1  months (IQR: 
3.7‐23.6 months).
We detected myosteatosis in 72 patients (58.5%). Patients 
with myosteatosis were older, had a higher BMI, and lost less 
weight compared to non‐myosteatosis individuals (Table 1). 
Interestingly, as shown in Table 2, patients with myosteato-
sis presented higher visceral, subcutaneous, and intramus-
cular adipose tissue depots compared to subjects without 
myosteatosis (Figure 1). We did not observe a difference 
in sarcopenia distribution between patients with or without 
myosteatosis.
3.2 | Survival analysis
Although we did not detect differences in response rate (par-
tial  +  complete response) between patients with (57.8%) 
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or without (67.2%) myosteatosis (P  =  .23), Kaplan‐Meier 
curves demonstrated that patients with myosteatosis pre-
sented better PFS (log‐rank P <  .001) (Figure 2A). A sig-
nificantly greater PFS related to myosteatosis was detected 
according to adjusted Cox regression analysis (HR: 0.53, 
95% CI, 0.34‐0.83; P = .005). Median PFS was 4.0 months 
in the non‐myosteatosis group vs 11.0 months for myostea-
tosis individuals (Table 3). The above‐described results were 
similar when PFS was calculated using as reference the date 
of performed CT instead of diagnosis date (Table S1).
Analysis of OS also showed statistically significant dif-
ferences between the myosteatosis and non‐myosteatosis 
groups. Kaplan‐Meier curves demonstrated that patients with 
myosteatosis presented better OS compared to those without 
myosteatosis (log‐rank P = .005) (Figure 2B). As shown in 








Age, mean (SD), y 59.3 (11.7) 56.1 (9.9) 61.6 (12.3) .01
Sex, no (%)
Male 107 (87.7) 45 (88.2) 63 (87.5) .90
Female 15 (12.3) 6 (11.8) 9 (12.7)  
Body mass index (kg/m2), no (%)
<18.5 41 (33.3) 25 (49.0) 16 (22.2) .02
18.5‐24.9 66 (53.7) 21 (41.2) 45 (62.5)  
25‐30 13 (10.6) 4 (7.8) 9 (12.5)  
>30 3 (2.4) 1 (2.0) 2 (2.80)  
Weight loss, no (%)
<5 8 (6.5) 3 (5.9) 5 (6.9) .04
5‐9.9 22 (17.9) 4 (7.8) 18 (25.0)  
>10 93 (75.6) 44 (88.3) 49 (68.1)  
Hypertension, no (%) 36 (29.3) 11 (21.6) 25 (34.7) .11
Dyslipidemia, no (%) 4 (3.2) 2 (3.9) 2 (2.7) .55
Diabetes, no (%) 5 (4.1) 2 (3.9) 3 (4.2) .66
Histology, no (%)       .32
Adenocarcinoma 11 (8.9) 3 (5.9) 8 (11.1)  
Squamous cell 
carcinoma
112 (91.1) 48 (94.1) 64 (88.9)  
Tumor location, no (%)
Upper third 15 (12.2) 3 (5.9) 12 (16.6) .19
Middle third 71 (57.7) 32 (62.7) 39 (54.2)  




19 (15.5) 7 (13.7) 12 (16.7) .88
Carboplatin + pacli-
taxel
102 (82.9) 43 (84.3) 59 (81.9)  
Others 2 (1.6) 1 (2.0) 1 (1.4)  
Toxicity grade III‐IV, no (%)
No 31 (25.2) 9 (17.7) 22 (30.6) .10
Yes 92 (74.8) 42 (82.3) 50 (69.4)  
ECOG, no (%)
0 58 (47.5) 22 (43.1) 36 (47.5) .33
1 60 (49.2) 26 (51.0) 60 (49.2)  
2 4 (3.3) 3 (5.9) 4 (3.3)  
Abbreviations: ECOG, Eastern Cooperative Oncology Group Performance; SD, standard deviation.
T A B L E  1  Selected characteristics 
according to myosteatosis of esophageal 
cancer patients
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T A B L E  2  Body composition and inflammatory indexes according to myosteatosis of esophageal cancer patients
Parameter All‐patients (n = 123)
No‐myosteatosis 
(n = 51) Myosteatosis (n = 72) P value
Skeletal muscle, mean (SD)
Area (cm2) 122.1 (24.5) 118.0 (27.2) 125.0 (22.0) .12
Mean MA (HU) 38.8 (9.3) 47.1 (6.4) 32.9 (5.7) <.01
SMI (cm2/m2) 44.7 (8.4) 43.2 (9.3) 45.7 (7.7) .10
Sarcopenia, no (%) 57 (46.3) 24 (47.1) 33 (45.8) .89
Adipose tissue, median (IQR)
Visceral, area (cm2) 25.1 (6.7‐102.0) 8.4 (1.3‐21.5) 65.9 (21.5‐135.2) <.01
VFI (cm2/m2) 8.6 (2.3‐38.3) 2.9 (0.6‐7.9) 25.4 (7.7‐52.3) <.01
Subcutaneous, area (cm2) 40.9 (13.6‐75.3) 19.0 (0.9‐48.3) 52.7 (29.0‐104.0) <.01
SFI (cm2/m2) 15.1 (4.6‐28.7) 6.9 (0.4‐17.9) 19.1 (10.5‐38.1) <.01
Intramuscular, area (cm2) 6.6 (2.9‐11.2) 2.9 (1.9‐6.5) 9.3 (5.7‐12.7) <.01
Inflammatory indexes
NLR, median (IQR) 2.8 (2.3) 3.8 (3.0) 2.6 (1.9) <.01
PLR, median (IQR) 133.1 (81.7) 153.7 (71.0) 118.4 (76.0) <.01
Abbreviations: HU, Hounsfield units; IQR, interquartile range; MA, muscle attenuation; NLR, neutrophil‐to‐lymphocyte ratio; SD, standard deviation; SFI, subcutane-
ous fat index; SMI, skeletal muscle index; VFI, visceral fat index.
F I G U R E  1  Representative computed tomography images in patients with (A—43 y old man with squamous cell carcinoma; BMI = 19.9; 
NLR = 8.8; PLR = 1871.0) and without (B—57 y old man with squamous cell carcinoma; BMI = 21.3; NLR = 2.4; PLR = 67.3) myosteatosis 
with LAEC treated with dCRT. PFS (C) and OS (D) in patients with and without myosteatosis with LAEC treated with dCRT. Color legend: 
Subcutaneous (blue), visceral (yellow), intramuscular adipose tissue (green), and skeletal muscle mass (red). BMI, body mass index; dCRT, 
definitive chemoradiotherapy; LAEC, locally advanced esophageal cancer; NLR, neutrophil‐lymphocyte ratio; PLR, platelet‐to‐lymphocyte ratio
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was detected according to adjusted Cox regression analysis 
(HR: 0.57; 95% CI, 0.36‐0.91; P =  .018). Median OS was 
9.8 months in the non‐myosteatosis group vs 15.3 months for 
individuals with myosteatosis (Table 3). Two‐year OS rates 
were 7.8% and 33.3% in the non‐myosteatosis and myoste-
atosis groups, respectively. The above‐described results were 
similar when OS was calculated using as reference the date of 
performed CT instead of diagnosis date (Table S1).
Given that body composition alterations could be asso-
ciated with early mortality, we performed sensitivity analy-
ses to evaluate the possibility of reversed causality. The PFS 
analysis excluding the patients in whom disease progressed 
within the first 3 months (31 patients) showed persistent sta-
tistical significance (HR: 0.58; 95% CI, 0.33‐0.99; P < .049). 
Similar results were obtained excluding the 23 patients who 
died within the first 3  months. Myosteatosis predicted in-
creased OS (HR: 0.54; 95% CI, 0.31‐0.93; P = .026).
Kaplan‐Meier curves also revealed that individuals with 
sarcopenia had similar PFS and OS compared with non‐sar-
copenia group (Figure S1). We failed to detect that SM area 
and SMI were associated with survival outcomes (Table S2). 
A higher visceral fat area and VFI were associated with better 
prognosis, in continuous analyses (Table S2). While, a NLR 
less than 2.8 was associated with decreased risk of disease 
progression (HR: 0.64; 95% CI, 0.42‐0.98; P  =  .042) and 
death (HR: 0.56; 95% CI, 0.36‐0.88; P = .012) (Table S2). 
Similarly, a PLR less than 133 was associated with improved 
prognosis (Table S2).
3.3 | Subgroup analysis by 
inflammatory indexes
There are some reasons to hypothesize that lower inflam-
matory indexes could discriminate a subgroup of LAEC 
patients where myosteatosis is not induced by cancer‐me-
diated inflammation and consequently this subgroup would 
have an increased survival. Firstly, increased inflammatory 
indexes are associated not only with cancer but also with 
increased visceral adiposity.31 Secondly, the absolute value 
of these indexes is lower in metabolic diseases than that 
in cancer.31,32 Finally, both visceral adiposity and cancer 
are associated with myosteatosis.33 In accordance with 
this hypothesis, subgroup analysis showed interaction be-
tween myosteatosis impact on survival outcomes (PFS and 
OS) and NLR  <  2.8 (P  <  .001), with patients who have 
NLR < 2.8 showing a more favorable prognosis, which was 
confirmed by multivariable analysis (Table 4). Whereas, 
patients with myosteatosis and NLR > 2.8 presented a very 
poor prognosis similar to patients without myosteatosis 
(Figure 2; log‐rank P < .001).
Among patients with myosteatosis, characteristics were 
similar between systemic inflammation‐categorized sub-
groups, except that patients with NLR  <  2.8 tended to be 
ECOG 0, while patients with NLR > 2.8 tended to be ECOG 
1 (P = .001; Table S3). Patients with NLR < 2.8 had an im-
proved PFS (HR: 0.47; 95% CI: 0.26‐0.85; P  =  .013) and 
OS (HR: 0.39; 95% CI, 0.21‐0.72; P  =  .003) (Table 4). 
Consistently, the survival outcomes analysis using standard 
cutoffs for low (<3) and high (>5) NLR showed persistent 
statistical significance.32 Among patients with NLR  <  3, 
myosteatosis predicted increased PFS (HR: 0.34; 95% CI, 
0.17‐0.68; P = .002) and OS (HR: 0.43; 95% CI, 0.26‐0.88; 
P = .021). Whereas, among patients with NLR > 5, myoste-
atosis did not affect PFS (HR: 0.59; 95% CI, 0.17‐2.26; 
P = .048) and OS (HR: 0.48; 95% CI, 0.18‐2.83; P = .72).
We obtained similar results when systemic inflammation 
subgroups were categorized by PLR (Figure S2; Table S4).
4 |  DISCUSSION
In this retrospective study, we found that myosteatosis was 
significantly associated with favorable PFS and OS in patients 
submitted to dCRT for LAEC, suggesting that myosteatosis 
F I G U R E  2  Progression‐free survival (A) and overall survival (B) according to neutrophil‐to‐lymphocyte ratio and myosteatosis in patients 
with locally advanced esophageal cancer treated with definitive chemoradiotherapy
   | 6973GABIATTI eT Al.
is a biomarker that may help to implement personalized nu-
tritional and therapeutic approaches. Furthermore, increased 
NLR was more frequently observed in patients without my-
osteatosis and subgroup analysis revealed that the co‐occur-
rence of myosteatosis and low NLR predicted a less than half 
disease progression and mortality risks in LAEC patients 
treated with dCRT.
The European Society for Parenteral and Enteral nutri-
tion guidelines strongly recommend that patients submitted 
to esophageal radiotherapy should be ensured an adequate 
nutritional support, which should include the use of nutri-
tional supplements.34 Interestingly, we observed a low prev-
alence of overweight and obesity in our population (15.3%). 
Furthermore, we did not detect visceral obesity and 93% of 
our cohort presented more than 5% weight loss. It is import-
ant to note that our data are in contrast to the prevalence of 
overweight and obesity, which reaches rates of up to 68%, 
in studies where adenocarcinoma was the main histological 
type and the patients were submitted to esophagectomy.35 
Altogether, these data suggest that individuals submitted to 
dCRT for esophageal cancer are extremely vulnerable and 
should have personalized nutritional counseling.
In striking contrast to previous reports,12,17-19 our data 
show that myosteatosis predicted a favorable prognosis. The 
pathophysiological mechanisms associated with increased 
intramyocellular lipid deposits with cancer‐mediated weight 
loss are still not clear36; however, enhanced lipolysis, insulin 
resistance, and impaired mitochondrial oxidation are often 
implicated in the myosteatosis formation.6,37-39 Notably, these 
phenomena are associated with enhanced inflammatory mi-
lieu,6,39 suggesting that the individual inflammatory status 
may identify distinct myosteatosis pathophysiology that could 
modulate survival outcomes. In accordance with this hypothe-
sis, we observed that the combination of low systemic inflam-
mation with myosteatosis revealed a subgroup with improved 
prognosis. These results indicate that intramuscular fat depots 
that are not associated with cachexia‐mediated inflammation 
may be a protective factor. Moreover, low visceral fat content 
worsens prognosis 40 and a recent report showed that diabetes 
was independently associated with better prognosis in LAEC 
subjects.4 Consistently, our results demonstrate that patients 
with myosteatosis presented increased adipose tissue in vis-
ceral, subcutaneous, and muscular areas. Although no patient 
presented visceral obesity, analysis of high visceral fat area 
and VFI as continuous variables showed that they were in-
dependently associated with decreased OS. Therefore, these 
data also suggest that the presence of myosteatosis may be a 
surrogate marker of adipose tissue depots in LAEC patients.
The thrifty metabolic phenotype hypothesis is currently ac-
cepted as the individual ability of increasing or decreasing their 
energy conservation machinery during famine and overfeeding 
circumstances.41-43 In accordance, one of the best methods to 
predict individual propensity to weight gain is to measure en-
ergy expenditure in individuals submitted to low protein over-
feeding, therefore individuals who more efficiently decrease 
energy expenditure during low energy intake tend to gain more 
weight.42,44 Our study shows that individuals with mechanical 







#Events/at risk 44/51 53/72  
Median (mo) 4.0 11.0  
Age‐adjusted Referent 0.49 (0.32‐0.75) .001
Adjusteda Referent 0.53 (0.34‐0.83) .005
Overall survival
#Events/at risk 41/51 49/72  
Median (mo) 9.8 15.3  
Age‐adjusted Referent 0.58 (0.38‐0.89) .013
Adjusteda Referent 0.57 (0.36‐0.91) .018
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology 
Group Performance.
aCox model adjusted for age (continuous), weight loss (<5%, 5‐9.9, or >9), BMI 
(<18.5, 18.5‐24.9, 25‐30, or >30), and ECOG (0, 1, or 2). 
T A B L E  4  Myosteatosis, neutrophil‐to‐lymphocyte ratio, and survival from date of treatment start
 
Progression‐free survival Overall survival
No myosteatosis Myosteatosis No myosteatosis Myosteatosis
NLR < 2.8 NLR > 2.8 NLR < 2.8 NLR > 2.8 NLR < 2.8 NLR > 2.8 NLR < 2.8 NLR > 2.8
#Events/at risk 29/34 15/17 26/44 27/28 27/34 14/17 26/44 23/28
Median (mo) 4.4 3.9 24.0 8.4 9.8 10.1 30.8 10.4
HR 1.328 0.469 1.178 0.388
95% CI 0.698‐2.526 0.259‐0.851 0.611‐2.270 0.208‐0.724
P .388 .013 .625 .003
Note: Cox model adjusted for age (continuous), weight loss (<5%, 5‐9.9, or >9), BMI (<18.5, 18.5‐24.9, 25‐30, or >30), and ECOG (0, 1, or 2).
Abbreviations: BMI, body mass index; ECOG, Eastern Cooperative Oncology Group Performance; NLR, neutrophil‐to‐lymphocyte ratio.
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obstruction of the esophagus that accumulated larger amounts 
of adipose tissue depots without cancer cachexia‐mediated in-
flammation lived longer. These results are also in agreement 
with the hibernation theory, a hypothesis that is used to explain 
the paradox of obesity whereby as high are energy storages 
more protected are the individual from long periods of fast-
ing and therefore present favorable cancer‐related outcomes.45 
In aggregate, it is tempting to speculate that obesity paradox 
promoted by the hibernation hypothesis is more likely to hap-
pen in cancer cachexia where reduced ingestion becomes the 
preponderant factor concomitant to the absence of the overt of 
cachexia‐mediated inflammation. These data also suggest that 
individuals with LAEC and a higher capacity to decrease their 
energy expenditure will have better prognosis. Given that a pre-
vious report observed that adipose tissue distribution between 
subcutaneous and visceral depots may directly influence OS,46 
further studies are needed to elucidate how cachexia‐mediated 
inflammation modulate this association.
A large number of studies evaluated the role of sarcopenia 
on survival outcomes after esophagectomy. In spite of some 
studies suggesting that sarcopenia had no impact on OS,47-49 
a recent meta‐analysis15 showed that sarcopenia is in fact an 
unfavorable prognostic factor. In contrast, sarcopenia in met-
astatic esophageal carcinoma setting was not associated with 
mortality.16,50 On the other hand, the prognostic significance 
of sarcopenia in patients with LAEC is not well established. 
We found three studies that evaluate this setting of patients. 
These studies showed that sarcopenia was not associated with 
mortality in multivariate analysis.50-52 In accordance with 
these results, we also did not detect a role for sarcopenia in 
predicting prognosis in this analysis. Otherwise, we did not 
observe that a low muscle index, analyzed as a continuous 
variable, was associated with poor prognosis in contrast to 
the previous report of Järvinen et al.50
Strengths of our study comprise its large sample of subjects 
submitted to dCRT in a tertiary hospital. As far as we know, 
this is the largest study in this setting of patients. Furthermore, 
it involves a unique kind of cancer population that the cachectic 
phenotype is mainly determined by mechanical obstruction of 
digestive tract. On the other hand, we have limited information 
on tumor and lymph node staging since the patients were not 
submitted to endoscopic ultrasonography. Furthermore, the 
study's retrospective and single‐centered nature as well as the 
complexity inherent to the method of defining patient myoste-
atosis presence limits its generalizability and clinical utilization.
In conclusion, myosteatosis without systemic inflammation 
predicted favorable prognosis in patients treated with dCRT for 
LAEC. Further studies that prospectively explore the role of 
myosteatosis and inflammatory status as a potential modifiable 
biomarker may help to strategically build nutritional and phar-
macologic interventions that ultimately can improve both our 
understanding of the involved pathophysiological mechanisms 
as well as the prognosis of esophageal cancer patients.
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